Theralase Technologies ( #TSXV: $TLT | #OTCQB: #TLTFF ) CEO Roger White compared the company's four-hour bladder cancer treatment with bladder removal surgery, a seven-hour procedure that he noted carries risk even with skilled surgeons.

Watch: youtu.be/yeFJUx2w9d8?...

Theralase Technologies ( #TSXV: $TLT | #OTCQB: #TLTFF ) is developing a light-activated drug designed to target cancer cells. CEO Roger White shared the case of a study patient who retained their bladder seven years after a single treatment.

Watch: youtu.be/yeFJUx2w9d8?...

Theralase Technologies ($TLT | #TLTFF) is advancing a light-activated approach to treating BCG-unresponsive bladder cancer. CEO Roger Dumoulin-White discusses Ruvidar®’s Phase II progress and its drug-light activation system.

Watch: www.youtube.com/watch?v=sb-_...